Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Ingelheim, Germany Saturday, February 15, 2025, 12:00 Hrs [IST] ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...
Seattle, Wash., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Greater Good Charities is teaming up with Boehringer Ingelheim for the global nonprofit’s annual Shelter Bowl event. The event will donate ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
The Campaign will Donate Millions of Meals and Thousands of Doses of NexGard® PLUS (afoxolaner, moxidectin, and pyrantel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback